期刊文献+

探讨两种方案治疗Ⅱ~Ⅳ期宫颈癌临床疗效和安全性差异 被引量:2

Clinical efficacy and safety of two different regimens in the treatment of stage Ⅱ-Ⅳ cervical cancer
暂未订购
导出
摘要 目的:探讨两种方案治疗Ⅱ~Ⅳ期宫颈癌临床疗效和安全性差异。方法:回顾性分析我院2012年9月至2015年9月接诊的90例Ⅱ~Ⅳ期宫颈癌患者的临床资料,按照随机数表法,将所有患者均分为两组,即A组和B组,每组患者均有45例患者,A组采用三维适形放疗联合紫杉醇+奈达铂调强放疗,B组采用紫杉醇+奈达铂常规放疗,比较两组不同的治疗方案临床疗效、患者2年生存率以及药物的不良反应情况。结果:A组治疗后的有效率为95.6%,显著高于B组的82.2%(P<0.05);A组治疗后的2年生存率为80.0%,显著高于B组的60.0%(P<0.05);A组出现腹泻13例、白细胞降低28例、恶心呕吐21例以及食欲不振20例,B组分别出现23、36、34以及31例,A组的不良反应发生率明显更低(P<0.05)。结论:三维适形放疗联合紫杉醇+奈达铂调强放疗,其临床疗效和生存率都高,紫杉醇+奈达铂调强放疗后的药物不良反应发生率较低,安全性更高,临床价值较高,值得推广应用。 Objectives: To investigate the clinical efficacy and safety of two different regimens in the treatment of cervical cancer stage Ⅱ-Ⅳ. Methods: Retrospective analysis was done on the clinical data of 90 patients with stage Ⅱ-Ⅳ cervical cancer in our hospital from September 2012 to September 2015. According to the random number table method,all patients were divided into two groups,group A and group B,with 45 cases in each group.Group A was treated with three-dimensional conformal radiotherapy combined with paclitaxel + nedaplatin + yew IMRT,and group B was treated with conventional radiotherapy paclitaxel + nedaplatin. Adverse reactions were compared between the two groups. The clinical curative effect,2-year survival rate and adverse reaction were compared. Results: After treatment,the effective rate of group A was 95. 55%,which was significantly higher than that of group B( 82. 22%,P 0. 05); the 2-year survival rate of group A was 80%,which was significantly higher than that of group B( 60. 00%,P 0. 05); there were 13 cases of diarrhea,28 cases of leukopenia,21 cases of nausea and vomiting and 20 cases of loss of appetite in group A. In group B,there were 23 cases of diarrhea,36 cases of leukopenia,34 cases of nausea and vomiting and 31 cases of loss of appetite. Adverse reaction rate in group A was significantly lower,with statistically significant difference( P 0. 05). Conclusion: Three-dimensional conformal radiotherapy combined with paclitaxel and nedaplatin in intensity-modulated radiotherapy has high clinical curative effect and survival rate,with low incidence of adverse reaction,high safety,and high clinical value,which is worthy of promotion and application.
出处 《中国性科学》 2017年第12期31-33,共3页 Chinese Journal of Human Sexuality
关键词 宫颈癌 三维适形放疗 紫杉醇 奈达铂 Cervical cancer Three- dimensional conformal radiotherapy Paelitaxel Nedaplatin
  • 相关文献

参考文献15

二级参考文献140

  • 1包德强,黄超红,张钰瑜,银正民,李斌,谢聘婷.复发性宫颈癌30例三维适形放射治疗的疗效观察[J].实用癌症杂志,2010,25(5):487-488. 被引量:7
  • 2陆红霞,徐丛剑,李斌.紫杉醇剂型、临床用药方式及联合用药的研究进展[J].国外医学(药学分册),2005,32(2):73-77. 被引量:11
  • 3糜若然,陈星.宫颈癌新辅助化疗的评价[J].国外医学(妇产科学分册),2006,33(1):61-63. 被引量:22
  • 4贾颖,瞿全新.宫颈癌同步放化疗临床应用进展[J].国外医学(妇产科学分册),2006,33(2):120-123. 被引量:16
  • 5陈宏伟,范俊杰,罗伟,宋玉霞,李明众.宫颈癌热放化随机分组治疗[J].中国肿瘤临床,1997,24(4):249-251. 被引量:2
  • 6Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carbo- platin is an effective nonanthraeyeline -containing regimen as neo- adjuvant chemotherapy for brease cancer[ J]. Ann Oncol, 2010,21 (5) :961-967.
  • 7Yeo KO, Hyun JL, Mi-Hee J, et al. Role of activating transcrip- tion factor 3 on tap73 stability and apoptosis in paclitaxel treated cervical cancer cells [ J ]. Molecular Cancer Research, 2008,6 (7) :1232-1249.
  • 8Kuh HJ, Jang SH, Wientjes MG, et al. Computational model of intracellular pharmacokinetics of paclitaxel [ J ]. J Pharmacol Exp Ther, 2000,293(3) :761-770.
  • 9Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer ceils for 1 week in vivo and in vitro [ J ]. Cancer Che- mother Pharmacol, 2006,58 (5) :665-672.
  • 10Sehouli J, Stengel D, Mustea A. Weekly paclitaxel and carboplatin for patients with primary advanced ovarian cancer: results of a mul- ticenter phase-II study of the NOGGO [ J ]. Cancer Chemother Pharmaeol, 2008,61 (2) :243-250.

共引文献294

同被引文献16

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部